Browse the evidence

Basal glucose homeostasis is governed by insulin-independent mechanisms primarily regulated by the brain, whereas glucose tolerance is determined by the interaction between insulin secretion and insulin sensitivity.

Understanding that fasting blood sugar (basal state) and how your body handles meals (glucose tolerance) are controlled by different systems can explain why some treatments work for one but not the other. Fasting glucose is largely managed by brain-mediated, insulin-independent processes, while meal response relies on insulin. This suggests that therapies targeting the brain (like certain GLP-1 agonists) may help basal glucose even if they don't fully restore insulin sensitivity.

Aging is associated with impaired glucose tolerance due to reduced insulin sensitivity and failure of insulin secretion to compensate, without changes in basal glucose or insulin-independent glucose disposal.

As you age, your body's ability to handle sugar after meals (glucose tolerance) declines due to insulin resistance and insufficient insulin response, but your fasting blood sugar may remain normal. This highlights the importance of monitoring post-meal glucose in older adults.

SGLT2 inhibitors reduce cardiovascular risk through mechanisms including osmotic diuresis, blood pressure reduction, weight loss, and reduced arterial stiffness, independent of glucose lowering.

SGLT2 inhibitors like empagliflozin help the heart by lowering blood pressure, reducing body weight (specifically fat mass), and making arteries more flexible. These physical changes reduce the workload on the heart and lower the risk of heart failure and cardiovascular death, offering benefits beyond just controlling blood sugar.

Thyroid hormone substitution therapy in hypothyroid patients produces only modest weight loss (3-5 kg) and does not resolve obesity; therefore, obesity treatment should not be delayed until thyroid levels are normalized.

Do not wait for your thyroid levels to normalize before starting weight loss efforts. Thyroid medication will only help you lose a small amount of weight (3-5 kg). Focus on behavioral changes (diet and exercise) and other obesity treatments immediately, as these are the primary drivers of weight loss.

Statins are safe and beneficial for patients with chronic liver disease (excluding decompensated cirrhosis), improving overall survival and reducing hepatic decompensation risk, contradicting the historical dogma that they are contraindicated.

If you have fatty liver disease and high cholesterol or heart disease risk, take your statin as prescribed. It is safe for your liver (unless you have advanced, decompensated cirrhosis) and helps you live longer.

Central (aortic) blood pressure is a stronger predictor of future cardiovascular risk and target organ damage than peripheral (brachial) blood pressure because vital organs are more directly exposed to central pressure.

If you have obesity or hypertension, ask your doctor about central blood pressure assessment. Standard arm-cuff readings may underestimate the stress on your heart and kidneys. Central pressure monitoring offers a more accurate prediction of long-term cardiovascular risk and organ damage.

Women with type 2 diabetes face a disproportionately higher relative risk of major cardiovascular complications compared to men with type 2 diabetes, despite having lower absolute incidence rates in the general population.

If you are a woman with type 2 diabetes, your risk of heart disease and stroke is significantly higher relative to your non-diabetic peers than it is for men with diabetes. This means you cannot rely on general 'average' risk calculators. You need more aggressive management of blood pressure, lipids, and blood sugar than men might require for similar risk profiles, and you should advocate for this heightened level of care with your healthcare provider.

Persistent psychological stress is causally associated with an increased risk of fatal or non-fatal coronary heart disease (CHD) events in a dose-dependent manner.

Chronic, unmanaged stress is a direct physical risk factor for heart attacks, not just a feeling. The risk increases with the frequency and persistence of stress. Managing stress is as critical for heart health as diet and exercise because it reduces the biological 'allostatic load' that damages blood vessels and heart tissue over time.

The phenotype of 'metabolically healthy obesity' (MHO) is a transient state that progresses over time to an unhealthy phenotype, particularly in children and adolescents, and is associated with increased cardiovascular risk compared to metabolically healthy normal weight individuals.

Even if your blood pressure and cholesterol are normal, having obesity is not 'healthy' in the long term. It is a temporary state that often leads to metabolic problems like diabetes and heart disease, especially as you age. You should still focus on maintaining a healthy weight and physical fitness to prevent this progression.

Alternate-day fasting does not significantly improve high-density lipoprotein (HDL), fasting blood sugar (FBS), or homeostasis model assessment-insulin resistance (HOMA-IR) compared to control groups in the short term.

While ADF helps with weight and cholesterol, you should not expect it to automatically fix your blood sugar or insulin resistance in the short term (under 12 weeks). If you have insulin resistance, you may need to combine ADF with exercise or other strategies.

Phentermine/Topiramate increases the risk of psychological side effects including depression, anxiety, sleep disorders, and irritability.

Avoid Phentermine/Topiramate if you have a history of psychiatric disorders, as it increases the risk of anxiety, sleep issues, and irritability. Other options like Tirzepatide or Semaglutide may be safer for mental health.

Augmenting a hypocaloric ketogenic diet with exogenous ketone salts does not improve body composition outcomes (weight loss, fat loss, or lean mass preservation) compared to a ketogenic diet alone.

If you are doing a ketogenic diet for weight loss, adding exogenous ketone salts will not help you lose more fat or keep more muscle compared to doing the diet without them. The diet itself is the driver of body composition changes. You can save money by skipping the ketone salts.

Tirzepatide significantly increases the risk of gastrointestinal adverse events, including nausea, vomiting, and diarrhea, compared to placebo.

Be prepared for potential stomach issues like nausea, vomiting, and diarrhea when starting tirzepatide. These side effects are common and significantly more likely than with a placebo. Starting at a low dose and increasing slowly can help your body adjust. If side effects are severe, talk to your doctor about adjusting your dose or stopping the medication.

Time-restricted eating (TRE) significantly increases low-density lipoprotein (LDL) cholesterol levels in adults with overweight and obesity, although it does not significantly alter total cholesterol, HDL, or triglycerides.

While TRE helps reduce body fat, be aware that it may slightly increase your LDL ('bad') cholesterol. This increase was statistically significant but the authors note it does not pose a significant safety concern for most. If you have existing heart conditions or high cholesterol, monitor your levels and consult a doctor.

Adaptive thermogenesis (AT) is primarily mediated by hormonal signals (leptin and insulin) that downregulate substrate cycling in skeletal muscle, reducing energy expenditure to preserve fat stores.

Understanding that hormones like leptin and insulin drive metabolic slowdown helps explain why weight loss stalls. This is not just 'willpower'; it is a hormonal defense of fat stores. Strategies that maintain muscle mass and avoid extreme deficits may mitigate the severity of this hormonal suppression.

A 12-month 4:3 intermittent fasting protocol does not produce different changes in fasting appetite-related hormones (leptin, ghrelin, PYY, BDNF, adiponectin) compared to daily caloric restriction when energy deficits are matched.

Don't expect intermittent fasting to magically fix your hunger hormones differently than daily calorie counting. The benefit of 4:3 IMF comes from how it changes your eating behaviors and psychological relationship with food, not from a unique hormonal advantage.

A modest reduced-calorie diet does not significantly alter plasma levels of Brain-Derived Neurotrophic Factor (BDNF) or glycemic factors (glucose, insulin, HOMA-IR) in overweight/obese adults with cardiovascular risk factors over a two-month period.

While cutting calories helps your cholesterol and blood pressure, it might not immediately change your blood sugar levels or brain-derived neurotrophic factor (BDNF) levels in just two months. This doesn't mean the diet isn't working; it means these specific markers may take longer to respond or may not respond in everyone, especially if you are already on medication. Focus on the improvements you can see, like weight and lipid profiles.

Time-restricted feeding does not significantly improve cardiometabolic markers (HDL, LDL, triglycerides) compared to control diets in overweight or obese adults.

Do not expect time-restricted feeding to automatically improve your cholesterol or triglyceride levels. While it helps with weight loss, you may need to focus on other dietary factors or exercise to improve your lipid profile.

Insulin resistance directly causes cardiovascular disease through three primary mechanisms: signal transduction alteration, impaired substrate metabolism regulation, and altered substrate delivery to the myocardium.

If you have insulin resistance (often associated with obesity or type 2 diabetes), you are at higher risk for heart disease regardless of your cholesterol levels. Addressing insulin sensitivity through lifestyle changes is critical for heart health.

Insulin resistance leads to endothelial dysfunction by selectively impairing nitric oxide (NO) production while activating pro-inflammatory and pro-thrombotic pathways, contributing to hypertension and atherosclerosis.

Insulin resistance damages the lining of your blood vessels (endothelium) by reducing nitric oxide production. This leads to higher blood pressure and increased risk of heart disease. Improving insulin sensitivity helps protect your blood vessels.

Metabolic endotoxaemia, characterized by elevated circulating lipopolysaccharides (LPS) due to increased gut permeability, drives low-grade chronic inflammation associated with type 2 diabetes, NAFLD, and obesity.

High-fat diets can increase gut permeability, allowing lipopolysaccharides (LPS) from Gram-negative bacteria to enter the bloodstream. This triggers a low-grade inflammatory response via Toll-like receptors, contributing to insulin resistance and metabolic diseases like type 2 diabetes and NAFLD. Managing fat intake and supporting gut barrier integrity are key to reducing this inflammatory burden.

Obesity-induced inflammation involves a shift in adipose tissue macrophages from an anti-inflammatory M2 state to a pro-inflammatory M1 state, which secretes cytokines like TNF-α that block insulin signaling.

In obese individuals, fat tissue isn't just storage; it becomes an active immune organ. Fat cells attract immune cells that switch to a 'pro-inflammatory' mode (M1 macrophages), releasing chemicals like TNF-α that block insulin from working properly. Reducing this specific type of immune activation in fat tissue is key to improving metabolic health.

Inhibition of specific inflammatory signaling pathways (NF-κB and JNK) can disrupt the link between obesity and insulin resistance, suggesting these pathways are therapeutic targets.

Targeting the specific inflammatory signaling pathways (like JNK and NF-κB) that are overactive in obesity may help restore insulin sensitivity. While drugs targeting these are in development, current lifestyle interventions that reduce overall inflammation may indirectly modulate these pathways.

Metformin is the first-line oral pharmacological treatment for Type 2 Diabetes Mellitus (T2DM) across all age groups, primarily by activating AMPK to inhibit hepatic gluconeogenesis and sensitizing peripheral tissues to insulin.

Metformin is the standard first-line medication for Type 2 Diabetes. It works by helping your liver produce less sugar and your body use insulin better. It typically lowers blood sugar by 1-2% without causing weight gain. If you have kidney issues, your doctor may adjust the dose or avoid it. Start with a low dose to minimize stomach upset.